Specifically in melanoma, PTX has been tested as an adjuvant and neoadjuvant treatment at subtoxic doses and can inhibit melanoma tumor growth and angiogenesis by targeting the STAT3 signaling pathway. Here, STAT3 is linked to melanoma.